Oxford

Futó vizsgálatok

• Toboroz

  Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· 1/2. fázis· Forrás

• Toboroz

  Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  NCT07509151· 3. fázis· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· Forrás

• Toboroz

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· 4. fázis· Forrás

• Toboroz

  A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  NCT06564038· 1/2. fázis· Forrás

• Fut, nem toboroz

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· 3. fázis· Forrás

• Toboroz

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· 1/2. fázis· Forrás

• Fut, nem toboroz

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· 3. fázis· Forrás

• Toboroz

  Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

  NCT06005493· 1/2. fázis· Forrás

• Toboroz

  Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT05702229· 2. fázis· Forrás

• Fut, nem toboroz

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· 3. fázis· Forrás

• Toboroz

  Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

  NCT05557695· Forrás

• Fut, nem toboroz

  Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

  NCT04644068· 1/2. fázis· Forrás

• Fut, nem toboroz

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

  NCT03742102· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  NCT03328273· 1. fázis· Forrás

• Fut, nem toboroz

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· 2. fázis· Forrás

• Fut, nem toboroz

  Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

  NCT02264678· 1. fázis· Forrás

• Fut, nem toboroz

  ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

  NCT02029443· 1/2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus limfoid leukémia (CLL)4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hodgkin-limfóma1 toboroz
• Köpenysejtes limfóma1 toboroz
• Prosztatarák1 toboroz
• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Toboroz

  AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  NCT06219941· 2. fázis· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Forrás

• Lezárult

  Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT05216835· 1. fázis· Forrás

• Lezárult

  An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

  NCT04201262· 3. fázis· Forrás

• Lezárult

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· 3. fázis· Forrás

• Lezárult

  A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

  NCT02616666· 4. fázis· Forrás